TELA Bio, Inc.

NASDAQ:TELA

Medical - Devices

Healthcare
$1.14 +8.26%

+$0.09 today

Market cap
$51.00M
Beta
1.36
P/E (TTM)
-1.5
EPS (TTM)
-$0.72
52W Low $0.50High $1.69

Volume 0.22M

Average 0.17M

TELA Income Before Tax

Profit after all operating and non-operating items but before income tax.

TELA Bio, Inc.NASDAQ: TELA

Income Before Tax · Q2 FY2026 · quarter ended Jun 2026

Income before tax remains negative

Q2 FY2026 income before tax was -$11.2M, compared with -$9.89M a year earlier. Trailing-twelve-month income before tax was -$40.91M.

Context

  • Income before tax amounted to 48.1% of revenue in FY2025, down 6.7 pp from a year earlier.
  • Income before tax grew in size in 2 of the last 3 fiscal years.

What to watch

Whether quarterly income before tax holds near -$11.2M or moves back toward the trailing-twelve-month quarterly average of -$10.23M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$11.2M+8.3% QoQ
Last fiscal yearDec 2025
-$38.6M-1.6% YoY
LTMJun 2026
-$40.91M-0.2% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-13.3%——
1 year-1.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(38.6M) USD
Year-over-year change
-1.6%

Income Before Tax vs competitors

How TELA compares with its peers on the latest reported figures

  • TELA's LTM Jun 2026 income before tax of -$40.91M is the 8th highest of the 9 companies compared; the peer median is -$19.04M.
  • Its year-over-year change of -0.2% is the 3rd highest of 9, against a peer median of -26.9%.
  • Income before tax amounts to 51.2% of revenue for TELA, versus a peer median of 498.4%.
TELA Competitors Peer median
Income Before Tax for TELA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SRTSSensus Healthcare, Inc.LTM Mar 2026-$11.4M -429.4%—50.6%
COEPCoeptis Therapeutics, Inc.LTM Mar 2026-$12.88M -14.0%—910.7%
MDAISpectral AI, Inc.LTM Mar 2026-$14.36M -61.5%—86.0%
CUECue Biopharma, Inc.LTM Mar 2026-$19.02M +53.1%—58.1%
EQEquillium, Inc.LTM Mar 2026-$19.06M -39.8%——
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026-$24.54M -1.8%—1070.3%
SPRBSpruce Biosciences, Inc.LTM Mar 2026-$37.19M +32.9%——
TELATELA Bio, Inc.LTM Jun 2026-$40.91M -0.2%—51.2%
OTLKOutlook Therapeutics, Inc.LTM Mar 2026-$62.51M -395.9%—18764.2%
Peer median (excluding TELA) -$19.04M-26.9%—498.4%

Competitors are the stored peer set for TELA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue29.46M41.42M58.45M69.3M80.28M
Cost of Revenue10.65M14.37M18.34M22.81M25.93M
Gross Profit18.81M27.04M40.11M46.49M54.34M
Gross Margin63.9%65.3%68.6%67.1%67.7%
Research & Development6.74M8.94M9.62M8.81M9.22M
Selling, General & Admin41.52M57.11M74.57M79.37M78.88M
Operating Expenses48.26M66.05M84.19M80.6M88.1M
Depreciation & Amortization535K1.19M808K1.01M1.01M
EBITDA(29.14M)(39.06M)(40.63M)(31.68M)(32.35M)
EBITDA Margin-98.9%-94.3%-69.5%-45.7%-40.3%
Operating Income(29.45M)(39.01M)(44.08M)(34.12M)(33.76M)
Operating Margin-100.0%-94.2%-75.4%-49.2%-42.0%
Interest Income00000
Interest Expense3.6M4.05M5.22M5.29M5.25M
Other Income / Expenses(3.83M)(5.29M)(2.59M)(3.87M)(4.85M)
Income Before Tax(33.28M)(44.3M)(46.66M)(37.99M)(38.6M)
Pre-Tax Margin-112.9%-106.9%-79.8%-54.8%-48.1%
Income Tax Expense000(144K)230K
Net Income(33.28M)(44.3M)(46.66M)(37.84M)(38.83M)
Net Margin-112.9%-106.9%-79.8%-54.6%-48.4%
EPS (Basic)(2.30)(2.73)(2.04)(1.33)(0.83)
EPS (Diluted)(2.30)(2.73)(2.04)(1.33)(0.83)
Weighted Avg Shares14.47M16.27M22.87M28.53M46.95M
Weighted Avg Shares (Diluted)14.47M16.27M22.87M28.53M46.95M

TELA Bio, Inc.

NASDAQ:TELA

Intrinsic Alpha fair value

Locked

Current Price

$1.14

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.